A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions

Inclusion Criteria:

* Patients must have histologically confirmed solid tumors with superficial lesions.
* Patients must have unresectable and standard therapies-resistant solid tumors.
* Patients must be ≥ 20 years of age.
* Patients must have a life expectancy ≥ 12 weeks.
* Patients must have measurable non-visceral lesion(s) that are evaluable by the mWHO response criteria.
* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
* Patients must have adequate key organ function (bone marrow, heart, lung, liver, renal, etc), as defined as

  * Absolute neutrophil count ≥ 1,500/μL.
  * Platelet count ≥ 100,000/μL.
  * Total bilirubin levels ≤ 1.5 x upper limit of normal (ULN).
  * AST/ALT levels ≤ 2.5 x ULN, or ≤ 5 x ULN if liver metastases are present.
  * creatinine ≤ 1.5 x ULN.
  * creatinine clearance (calculated) ≥ 60 mL/min/1.73 m\^2 for patients with creatinine \> 1.5 x ULN.
* Patients must have passed 4 weeks after the completion of prior therapy \[except bone metastasis therapy\], or passed 8 weeks if immuno checkpoint inhibitor was treated.
* Patients must be able to understand and willing to sign a written informed consent document.

Exclusion Criteria:

* Patients with a history of significant tumor bleeding, or coagulation or bleeding disorders.
* Patients with Grade 2 adverse events Grade 2 or greater, except alopecia, resulting from anticancer agents administered more than 4 weeks prior to TBI-1401(HF10) administration.
* Patients receiving anti-herpes medication \[except local treatment such as ointment\].
* Patients receiving steroids or immunosuppressive agents \[except inhaled steroid\].
* Patients with clinically evident Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C virus (HCV) infection.
* Patients receiving anti-platelet medication.
* Patients receiving anti-coagulation medication.
* Patients with presence or medical history of central nervous system metastasis.
* Patients with Grade ≥ 2 pre-existing neurologic abnormalities (CTCAE version 4.0).
* Patients with severe cardiac disorder or abnormal cardiac rhythm.
* Patients with psychiatric disorder or drug dependency which affects informed consent.
* Pregnant or breastfeeding women; women or men, having normal reproductive potential, who disagree with the protection of pregnancy within the timeframe of the study.
* Patients received any other investigational products within 4 weeks, or within 8 weeks if immuno checkpoint inhibitor was treated.
* Patients would limit compliance with study requirements, as determined by the investigator.